|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
60 avenue Rockefeller, 69008 LYON, France, Bioserra 1, Bâtiment B, Lyon, Rhône-Alpes 69008, FR
|
|
ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function.
The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome, and liver diseases (such as Non-Alcoholic SteatoHepatitis, NASH). Roughly 30-50% of NASH patients have CKD through common bidirectional pathways leading to severe renal impairment.
Liver-related infectious diseases such as chronic Hepatitis B and Hepatitis D are also addressed with Vonafexor.
|
ENYO Pharma Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used ENYO Pharma email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact ENYO Pharma customer service number in your country click here to find.
Carole Dubreuil is the CEO of ENYO Pharma. To contact Carole Dubreuil email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.